Annual Total Liabilities
$50.87 M
-$15.56 M-23.43%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual total liabilities is $50.87 million, with the most recent change of -$15.56 million (-23.43%) on December 31, 2023.
- During the last 3 years, PLX annual total liabilities has fallen by -$44.11 million (-46.44%).
- PLX annual total liabilities is now -63.74% below its all-time high of $140.28 million, reached on December 31, 2013.
Performance
PLX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$29.13 M
-$33.83 M-53.74%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly total liabilities is $29.13 million, with the most recent change of -$33.83 million (-53.74%) on September 30, 2024.
- Over the past year, PLX quarterly total liabilities has dropped by -$20.20 million (-40.95%).
- PLX quarterly total liabilities is now -79.24% below its all-time high of $140.32 million, reached on March 31, 2017.
Performance
PLX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PLX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.4% | -41.0% |
| 3 y3 years | -46.4% | -41.0% |
| 5 y5 years | -55.4% | -41.0% |
PLX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -36.2% | at low | -63.5% | at low |
| 5 y | 5-year | -56.0% | at low | -74.8% | at low |
| alltime | all time | -63.7% | >+9999.0% | -79.2% | >+9999.0% |
Protalix BioTherapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $29.13 M(-53.7%) |
| Jun 2024 | - | $62.96 M(+4.9%) |
| Mar 2024 | - | $60.04 M(+18.0%) |
| Dec 2023 | $50.87 M(-23.4%) | $50.87 M(+3.1%) |
| Sep 2023 | - | $49.32 M(-0.2%) |
| Jun 2023 | - | $49.42 M(-24.6%) |
| Mar 2023 | - | $65.55 M(-1.3%) |
| Dec 2022 | $66.43 M(-16.7%) | $66.43 M(-2.6%) |
| Sep 2022 | - | $68.22 M(-3.3%) |
| Jun 2022 | - | $70.53 M(-7.0%) |
| Mar 2022 | - | $75.88 M(-4.8%) |
| Dec 2021 | $79.70 M(-16.1%) | $79.70 M(-4.3%) |
| Sep 2021 | - | $83.27 M(-20.2%) |
| Jun 2021 | - | $104.36 M(+18.2%) |
| Mar 2021 | - | $88.29 M(-7.0%) |
| Dec 2020 | $94.97 M(-17.9%) | $94.97 M(-10.1%) |
| Sep 2020 | - | $105.63 M(-0.8%) |
| Jun 2020 | - | $106.47 M(-6.4%) |
| Mar 2020 | - | $113.76 M(-1.7%) |
| Dec 2019 | $115.71 M(+1.5%) | $115.71 M(-7.1%) |
| Sep 2019 | - | $124.58 M(+1.5%) |
| Jun 2019 | - | $122.73 M(+1.5%) |
| Mar 2019 | - | $120.90 M(+6.0%) |
| Dec 2018 | $114.01 M(+12.1%) | $114.01 M(-13.8%) |
| Sep 2018 | - | $132.19 M(+30.5%) |
| Jun 2018 | - | $101.29 M(-2.8%) |
| Mar 2018 | - | $104.24 M(+2.5%) |
| Dec 2017 | $101.67 M(+10.3%) | $101.67 M(+16.7%) |
| Sep 2017 | - | $87.13 M(+9.4%) |
| Jun 2017 | - | $79.67 M(-43.2%) |
| Mar 2017 | - | $140.32 M(+52.2%) |
| Dec 2016 | $92.20 M(+6.7%) | $92.20 M(+7.7%) |
| Sep 2016 | - | $85.58 M(-1.5%) |
| Jun 2016 | - | $86.84 M(+2.6%) |
| Mar 2016 | - | $84.66 M(-2.0%) |
| Dec 2015 | $86.38 M(-35.5%) | $86.38 M(-32.5%) |
| Sep 2015 | - | $128.00 M(-2.4%) |
| Jun 2015 | - | $131.09 M(-1.6%) |
| Mar 2015 | - | $133.20 M(-0.6%) |
| Dec 2014 | $133.96 M(-4.5%) | $133.96 M(+1.1%) |
| Sep 2014 | - | $132.49 M(-2.9%) |
| Jun 2014 | - | $136.44 M(-0.4%) |
| Mar 2014 | - | $136.99 M(-2.3%) |
| Dec 2013 | $140.28 M(+70.9%) | $140.28 M(+1.8%) |
| Sep 2013 | - | $137.86 M(+85.6%) |
| Jun 2013 | - | $74.29 M(-2.5%) |
| Mar 2013 | - | $76.22 M(-7.1%) |
| Dec 2012 | $82.08 M(+5.4%) | $82.08 M(+13.1%) |
| Sep 2012 | - | $72.61 M(-5.0%) |
| Jun 2012 | - | $76.44 M(+2.0%) |
| Mar 2012 | - | $74.92 M(-3.8%) |
| Dec 2011 | $77.88 M | $77.88 M(-0.4%) |
| Sep 2011 | - | $78.18 M(-3.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2011 | - | $80.59 M(+5.7%) |
| Mar 2011 | - | $76.22 M(+0.2%) |
| Dec 2010 | $76.05 M(-8.1%) | $76.05 M(-3.4%) |
| Sep 2010 | - | $78.69 M(+3.8%) |
| Jun 2010 | - | $75.78 M(-5.5%) |
| Mar 2010 | - | $80.23 M(-3.1%) |
| Dec 2009 | $82.79 M(+1180.8%) | $82.79 M(+929.3%) |
| Sep 2009 | - | $8.04 M(+10.6%) |
| Jun 2009 | - | $7.27 M(+10.0%) |
| Mar 2009 | - | $6.61 M(+2.3%) |
| Dec 2008 | $6.46 M(+45.2%) | $6.46 M(+19.9%) |
| Sep 2008 | - | $5.39 M(+1.6%) |
| Jun 2008 | - | $5.31 M(+4.5%) |
| Mar 2008 | - | $5.08 M(+14.0%) |
| Dec 2007 | $4.45 M(+64.6%) | $4.45 M(+5.0%) |
| Sep 2007 | - | $4.24 M(+30.0%) |
| Jun 2007 | - | $3.26 M(+19.1%) |
| Mar 2007 | - | $2.74 M(+1.3%) |
| Dec 2006 | $2.70 M(+139.3%) | $2.70 M(>+9900.0%) |
| Sep 2006 | - | $12.10 K(-10.4%) |
| Jun 2006 | - | $13.50 K(-76.8%) |
| Mar 2006 | - | $58.10 K(-94.9%) |
| Dec 2005 | $1.13 M(+1491.5%) | $1.13 M(+1722.6%) |
| Sep 2005 | - | $62.00 K(+7.3%) |
| Jun 2005 | - | $57.80 K(-16.7%) |
| Mar 2005 | - | $69.40 K(-2.3%) |
| Dec 2004 | $71.00 K(-9.9%) | $71.00 K(+15.8%) |
| Sep 2004 | - | $61.30 K(-9.1%) |
| Jun 2004 | - | $67.40 K(+9.4%) |
| Mar 2004 | - | $61.60 K(-21.8%) |
| Dec 2003 | $78.80 K(-0.4%) | $78.80 K(+24.7%) |
| Sep 2003 | - | $63.20 K(+2.4%) |
| Jun 2003 | - | $61.70 K(-23.9%) |
| Mar 2003 | - | $81.10 K(+2.5%) |
| Dec 2002 | $79.10 K(+2.3%) | $79.10 K(+20.9%) |
| Sep 2002 | - | $65.40 K(+6.5%) |
| Jun 2002 | - | $61.40 K(-12.4%) |
| Mar 2002 | - | $70.10 K(-9.3%) |
| Dec 2001 | $77.30 K(-86.2%) | $77.30 K(-42.3%) |
| Sep 2001 | - | $134.00 K(+1.9%) |
| Jun 2001 | - | $131.50 K(-80.7%) |
| Mar 2001 | - | $680.50 K(+21.4%) |
| Dec 2000 | $560.60 K(+22.0%) | $560.60 K(+43.3%) |
| Sep 2000 | - | $391.30 K(-0.5%) |
| Jun 2000 | - | $393.20 K(-7.0%) |
| Mar 2000 | - | $422.80 K(-8.0%) |
| Dec 1999 | $459.40 K(-67.6%) | $459.40 K(-19.8%) |
| Sep 1999 | - | $572.50 K(-20.8%) |
| Jun 1999 | - | $722.90 K(-39.8%) |
| Mar 1999 | - | $1.20 M |
| Dec 1998 | $1.42 M(-81.0%) | - |
| Dec 1997 | $7.47 M(+1.7%) | - |
| Dec 1996 | $7.34 M | - |
FAQ
- What is Protalix BioTherapeutics annual total liabilities?
- What is the all time high annual total liabilities for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual total liabilities year-on-year change?
- What is Protalix BioTherapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly total liabilities year-on-year change?
What is Protalix BioTherapeutics annual total liabilities?
The current annual total liabilities of PLX is $50.87 M
What is the all time high annual total liabilities for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual total liabilities is $140.28 M
What is Protalix BioTherapeutics annual total liabilities year-on-year change?
Over the past year, PLX annual total liabilities has changed by -$15.56 M (-23.43%)
What is Protalix BioTherapeutics quarterly total liabilities?
The current quarterly total liabilities of PLX is $29.13 M
What is the all time high quarterly total liabilities for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly total liabilities is $140.32 M
What is Protalix BioTherapeutics quarterly total liabilities year-on-year change?
Over the past year, PLX quarterly total liabilities has changed by -$20.20 M (-40.95%)